We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$191M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Consumer Staples 0.52%
3 Consumer Discretionary 0.08%
4 Financials 0.04%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
201
DELISTED
Invitae Corporation
NVTA
– –
-118,366
Closed -$1.21M
MRTX
202
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-273,000
Closed -$5.84M
SYNH
203
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-11,846
Closed -$488K
INFI
204
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-100,000
Closed -$527K
OTIC
205
DELISTED
Otonomy, Inc.
OTIC
– –
-235,986
Closed -$3.52M
GTS
206
DELISTED
Triple-S Management Corporation
GTS
– –
-11,147
Closed -$264K
DRNA
207
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-50,000
Closed -$268K
TRIL
208
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-30,000
Closed -$278K
PRAH
209
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-11,751
Closed -$502K
GWPH
210
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-13,109
Closed -$946K
MNK
211
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-2,673
Closed -$164K
AGN
212
DELISTED
Allergan plc
AGN
– –
-155,000
Closed -$41.5M
ALDR
213
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-200,000
Closed -$4.9M
HZNP
214
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-350,000
Closed -$5.8M
AKAO
215
DELISTED
Achaogen Inc
AKAO
– –
-60,000
Closed -$166K
ELGX
216
DELISTED
Endologix Inc
ELGX
– –
-2,500
Closed -$209K
PMC
217
DELISTED
PharMerica Corporation
PMC
– –
-16,841
Closed -$372K
SPNC
218
DELISTED
Spectranetics Corp
SPNC
– –
-267,070
Closed -$3.88M
GI
219
DELISTED
EndoChoice Holdings, Inc.
GI
– –
-25,000
Closed -$130K
NSPH
220
DELISTED
NANOSPHERE INC. COM NEW
NSPH
– –
-35,379
Closed -$28K
CELG
221
DELISTED
Celgene Corp
CELG
– –
-50,000
Closed -$5M
VXX
222
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
– –
-3,750
Closed -$1.06M
5 6 7 8
9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $191M of net new capital in Q2 2016, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $12.4M trimmed.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.